CO5251425A1 - Metodo y composiciones para administrar taxanos oralmente a pacientes humanos - Google Patents
Metodo y composiciones para administrar taxanos oralmente a pacientes humanosInfo
- Publication number
- CO5251425A1 CO5251425A1 CO00082131A CO00082131A CO5251425A1 CO 5251425 A1 CO5251425 A1 CO 5251425A1 CO 00082131 A CO00082131 A CO 00082131A CO 00082131 A CO00082131 A CO 00082131A CO 5251425 A1 CO5251425 A1 CO 5251425A1
- Authority
- CO
- Colombia
- Prior art keywords
- taxane
- human patients
- administered
- oral
- orally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16231099P | 1999-10-27 | 1999-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5251425A1 true CO5251425A1 (es) | 2003-02-28 |
Family
ID=22585092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00082131A CO5251425A1 (es) | 1999-10-27 | 2000-10-27 | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1225956A1 (no) |
JP (1) | JP2003512443A (no) |
KR (1) | KR20030019296A (no) |
CN (1) | CN1450923A (no) |
AU (1) | AU1104201A (no) |
BR (1) | BR0015149A (no) |
CA (1) | CA2389583A1 (no) |
CO (1) | CO5251425A1 (no) |
CZ (1) | CZ20021484A3 (no) |
HU (1) | HUP0203303A3 (no) |
IL (1) | IL149360A0 (no) |
MX (1) | MXPA02004164A (no) |
NO (1) | NO20022008L (no) |
PL (1) | PL354777A1 (no) |
RU (1) | RU2002113659A (no) |
SK (1) | SK5822002A3 (no) |
WO (1) | WO2001030448A1 (no) |
ZA (1) | ZA200203358B (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
JP2006514698A (ja) * | 2002-10-30 | 2006-05-11 | スフェリックス, インコーポレイテッド | ナノ粒子生物活性物質 |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
PE20060416A1 (es) * | 2004-08-03 | 2006-06-09 | Novartis Ag | Composicion de inhibidores de renina e inhibidores de proteinas de efusion |
CN101513395B (zh) * | 2008-02-20 | 2011-01-12 | 单宝华 | 紫杉醇类双层软胶囊口服制剂药物 |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
US9402812B2 (en) | 2009-09-23 | 2016-08-02 | Indu JAVERI | Methods for the preparation of liposomes |
WO2011139899A2 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
CA3212816A1 (en) * | 2021-03-17 | 2022-09-22 | Dompe' Farmaceutici Spa | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
CA2221444A1 (en) * | 1996-01-31 | 1997-08-07 | Steven B. Hansel | A method of making pharmaceutically active taxanes orally bioavailable |
EP0814081A1 (en) * | 1996-06-17 | 1997-12-29 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
DE69832173T2 (de) * | 1997-05-27 | 2006-08-03 | IVAX RESEARCH, INC., Miami | Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung |
GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
IL138767A0 (en) * | 1998-04-01 | 2001-10-31 | Rtp Pharma Inc | Anticancer compositions |
CA2371912C (en) * | 1999-05-21 | 2010-02-16 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
-
2000
- 2000-10-27 CA CA002389583A patent/CA2389583A1/en not_active Abandoned
- 2000-10-27 AU AU11042/01A patent/AU1104201A/en not_active Abandoned
- 2000-10-27 WO PCT/US2000/029633 patent/WO2001030448A1/en not_active Application Discontinuation
- 2000-10-27 IL IL14936000A patent/IL149360A0/xx unknown
- 2000-10-27 CN CN00815924A patent/CN1450923A/zh active Pending
- 2000-10-27 JP JP2001532859A patent/JP2003512443A/ja active Pending
- 2000-10-27 HU HU0203303A patent/HUP0203303A3/hu unknown
- 2000-10-27 CO CO00082131A patent/CO5251425A1/es not_active Application Discontinuation
- 2000-10-27 SK SK582-2002A patent/SK5822002A3/sk unknown
- 2000-10-27 MX MXPA02004164A patent/MXPA02004164A/es unknown
- 2000-10-27 EP EP00972373A patent/EP1225956A1/en not_active Withdrawn
- 2000-10-27 KR KR1020027005396A patent/KR20030019296A/ko not_active Application Discontinuation
- 2000-10-27 PL PL00354777A patent/PL354777A1/xx not_active Application Discontinuation
- 2000-10-27 RU RU2002113659/15A patent/RU2002113659A/ru not_active Application Discontinuation
- 2000-10-27 CZ CZ20021484A patent/CZ20021484A3/cs unknown
- 2000-10-27 BR BR0015149-1A patent/BR0015149A/pt not_active IP Right Cessation
-
2002
- 2002-04-26 NO NO20022008A patent/NO20022008L/no not_active Application Discontinuation
- 2002-04-26 ZA ZA200203358A patent/ZA200203358B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003512443A (ja) | 2003-04-02 |
NO20022008L (no) | 2002-06-19 |
CZ20021484A3 (cs) | 2003-12-17 |
KR20030019296A (ko) | 2003-03-06 |
SK5822002A3 (en) | 2003-01-09 |
MXPA02004164A (es) | 2002-10-17 |
PL354777A1 (en) | 2004-02-23 |
WO2001030448A1 (en) | 2001-05-03 |
HUP0203303A2 (hu) | 2003-02-28 |
HUP0203303A3 (en) | 2005-01-28 |
IL149360A0 (en) | 2002-11-10 |
CN1450923A (zh) | 2003-10-22 |
EP1225956A1 (en) | 2002-07-31 |
BR0015149A (pt) | 2002-10-29 |
NO20022008D0 (no) | 2002-04-26 |
CA2389583A1 (en) | 2001-05-03 |
AU1104201A (en) | 2001-05-08 |
RU2002113659A (ru) | 2004-01-27 |
ZA200203358B (en) | 2003-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
NO20014519L (no) | Apomorfin- og sildenafilpreparat | |
MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
NO20014842D0 (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
BRPI0414518A (pt) | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano | |
RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
PT1251850E (pt) | Utilizacao de uma preparacao de combinacao na terapia do cancro | |
WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
CA2368352A1 (en) | Method for treating neurodegeneration | |
TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
NZ516026A (en) | Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents | |
Susman | Relapsed Mantle Cell Lymphoma: Thalidomide Adds to Rituximab's Potency | |
RU2002113978A (ru) | Способ стимуляции моторной активности кишечника | |
RU2003124971A (ru) | Способ лечения больных с невротическими и соматоформными расстройствами | |
DK1265629T3 (da) | Anvendelse af væksthormon i lav dosis | |
RU2006138043A (ru) | Способ лечения инсульта с применением введения дефибриногенизирующих средств для достижения специфического характера дефибриногенизации | |
Kamimura et al. | Drug therapy for depression in Japan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |